Clinical Trials

Novel Angiogenesis Inhibitor To Be Tested Against Advanced Breast And Colorectal Cancers

Published in Women's Health Weekly, June 21st, 2001

On May 30, 2001, researchers at the University of California, Los Angeles, Jonsson Cancer Center launched several studies of treatments for advanced breast and colorectal cancers that attempt to starve tumors by cutting off the blood supply they need to grow and flourish.

The large studies are open at UCLA's Westwood campus and at more than 60 affiliated cancer network oncology offices throughout California and in Nevada and Montana.

Hundreds of patients are being sought to take part in three clinical trials to study the experimental anti-VEGF antibody (Avastin) in combination with chemotherapy on advanced breast and colorectal cancers. A product...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-06-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry